Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
10.48
Nov 04 • 3:59 PM ET Dollar change+0.48 Percentage change(4.80%)
Aftermarket Close
10.52
Aftermarket • 7:50 PM ET Dollar change+0.04 Percentage change(0.38%)
Index
RUT
Market Cap
1.80B
Enterprise Value
1.60B
Income
-121.08M
Sales
1.56M
Book/sh
1.43
Cash/sh
1.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
140
IPO
Jul 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1152.89
P/B
7.30
P/C
8.94
P/FCF
-
EV/EBITDA
-
EV/Sales
1026.41
Quick Ratio
10.63
Current Ratio
10.63
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-0.80
EPS next Y
-0.74
EPS next Q
-0.19
EPS this Y
5.15%
EPS next Y
7.30%
EPS next 5Y
10.61%
EPS past 3/5Y
9.99% -9.45%
Sales past 3/5Y
-21.31% -10.14%
EPS Y/Y TTM
15.36%
Sales Y/Y TTM
-62.28%
EPS Q/Q
11.98%
Sales Q/Q
-46.37%
Insider Own
13.68%
Insider Trans
0.21%
Inst Own
83.80%
Inst Trans
19.67%
ROA
-50.57%
ROE
-57.72%
ROIC
-48.87%
Gross Margin
-610.70%
Oper. Margin
-8411.27%
Profit Margin
-7756.37%
SMA20
7.36%
SMA50
9.74%
SMA200
58.90%
Trades
Shs Outstand
171.56M
Shs Float
148.14M
52W High
12.54 -16.46%
52W Low
2.24 367.86%
Volatility
10.52% 9.97%
ATR (14)
0.99
RSI (14)
53.26
Beta
2.20
Rel Volume
1.16
Avg Volume
3.59M
Volume
4,156,964
Perf Week
-11.78%
Perf Month
2.04%
Perf Quarter
26.27%
Perf Half Y
76.13%
Perf YTD
200.29%
Perf Year
165.99%
Perf 3Y
638.03%
Perf 5Y
-38.43%
Perf 10Y
-
Prev Close
10.00
Price
10.48
Change %
4.80%
Consensus
Strong Buy
Avg. Price Target
$14.82
Implied Upside
+41.4%
Analysts16incl. previous ratings
Rating Distribution12 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 29, 2026Initiated
JEF logoJJefferies
Buy$14+33.6%
Jun 04, 2026Initiated
LLeerink Partners
Outperform$12+14.5%
May 28, 2026Initiated
BBTIG Research
Buy$9-14.1%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$4.32-58.8%
Oct 02, 2025Initiated
JPM logoJJP Morgan
Overweight
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Overweight$7-33.2%
Jan 22, 2025Initiated
NNeedham
Buy$9-14.1%
Oct 02, 2024Initiated
GGuggenheim
Buy$10-4.6%
Jul 03, 2024Initiated
MS logoMMorgan Stanley
Overweight$7-33.2%
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+24.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
FounderMr. Sean McClain
Chief Business Officer & CFODr. Zachariah Jonasson Ph.D.
Senior VP & Chief Accounting OfficerMr. Todd Bedrick CPA
CVP of Finance & Head of Investor RelationsMr. Alexander Khan CPA
Chief Legal OfficerMs. Shelby Walker J.D.